IgM Protease Vaccine for Colostrum-Mediated Piglet Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Streptococcus suis in piglets are ineffective during the critical 2-3 weeks after weaning due to interference with maternally derived antibodies and lack of efficacy under practical conditions, especially in seropositive animals.
Innovation Solution
A vaccine comprising an IgM protease antigen of Streptococcus suis, administered to pregnant female pigs, induces protective antibodies in piglets through colostrum intake, providing immunity against Streptococcus suis infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If whole-cell bacterins are used for vaccination, then broad antigenic coverage is achieved, but vaccine efficacy is reduced due to poor immunogenicity and interference with maternal antibodies
Solution Approach 1:
The patent extracts the specific IgM protease antigen from the whole Streptococcus suis bacterin. This extraction focuses the vaccine on a single key virulence factor (IgM protease) that is sufficient to induce protective immunity, eliminating the complexity and interference problems associated with whole-cell vaccines while maintaining efficacy.
Solution Approach 2:
The patent applies local quality by targeting a specific functional region (IgM protease enzyme) rather than using uniform whole-cell antigens. The IgM protease antigen has localized immunogenic properties that specifically protect against the critical mechanism of immune evasion (IgM degradation), providing focused protection without the drawbacks of broad but ineffective whole-cell formulations.
2Reliability
If autogenous bacterins are used, then strain-specific protection is attempted, but sampling errors and empirical application result in inconsistent efficacy
Solution Approach 1:
The patent applies universality by developing a vaccine based on IgM protease antigen that is conserved across multiple Streptococcus suis serotypes. This single antigen provides broad protection against different strains without requiring separate autogenous vaccines for each strain, eliminating sampling errors and empirical trial-and-error approaches.
3Reliability
If sows are vaccinated with bacterins, then passive immunity transfer to piglets is attempted, but poor sow response results in insufficient maternal antibodies
Solution Approach 1:
The patent extracts the IgM protease antigen to create a highly immunogenic subunit vaccine for sows. This purified antigen elicits strong antibody responses in vaccinated sows, ensuring adequate passive immunity transfer to piglets through colostrum, overcoming the poor response to whole-cell bacterins.
4Reliability
If piglets are vaccinated early, then direct protection is provided, but maternal antibody interference prevents effective immune response
Solution Approach 1:
The patent applies preliminary action by vaccinating sows before parturition to establish protective antibodies in advance. These antibodies are then passively transferred to piglets through colostrum intake within 24-48 hours after birth, providing protection during the critical period when piglets are most vulnerable to Streptococcus suis infection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine effectively protects piglets aged 4-7 weeks post-weaning and beyond, reducing clinical signs and mortality associated with Streptococcus suis infections, even in the presence of maternal antibodies.
Implementation Method 1
A vaccine comprising an IgM protease antigen of Streptococcus suis, administered to pregnant female pigs, induces protective antibodies in piglets through colostrum intake
Implementation Method 2
provides protection against Streptococcus suis under these stressful circumstances early in life
Data Source
Figure 1
AI summary
The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method wherein a female pig is vaccinated in order to protect a piglet against Streptococcus suis through the intake of colostrum of the vaccinated female pig.